NS
NSPR.US InspireMD Inc
- Market cap
- USD 28.1M
- P/E
- -
- P/B
- 0.97x
- ROE
- -145.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NSPR.US undervalued?
Graham numberThe Graham number of InspireMD Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InspireMD Inc fundamental analysis
No fundamental analysis for InspireMD Inc yet.
InspireMD Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InspireMD Inc
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; C…
Full company profileInspireMD Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InspireMD Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.89M | 2.76M | 3.60M | 3.72M | 2.49M | 4.50M | 5.17M | 6.21M | 7.01M | 8.98M | 9.88M |
| Gross Profit | 102K | 585K | 995K | 756K | 83.0K | 754K | 1.12M | 1.81M | 1.51M | 2.65M | 204K |
| Operating Income | -7.65M | -8.23M | -7.61M | -9.82M | -10.4M | -14.7M | -18.7M | -21.1M | -33.5M | -49.1M | -51.2M |
| EBITDA | -7.46M | -8.05M | -7.46M | -9.66M | -10.2M | -14.6M | -18.5M | -19.6M | -31.7M | -48.2M | -31.3M |
| Net Income | -8.46M | -8.44M | -7.24M | -10.0M | -10.5M | -14.9M | -18.5M | -19.9M | -32.0M | -48.8M | -31.7M |
| EPS | -151,089 | -4,266 | -235 | -72 | -6.97 | -2.03 | -2.35 | -0.82 | -0.76 | -0.66 | -0.37 |
| Balance Sheet | |||||||||||
| Total Assets | 9.41M | 6.11M | 12.3M | 9.88M | 17.8M | 39.7M | 24.7M | 47.6M | 46.8M | 69.4M | 33.6M |
| Total Liabilities | 5.37M | 3.38M | 3.53M | 4.50M | 5.61M | 6.18M | 7.26M | 8.14M | 10.7M | 14.2M | 11.8M |
| Shareholders' Equity | 4.05M | 2.73M | 8.76M | 5.38M | 12.2M | 33.5M | 17.4M | 39.5M | 36.1M | 55.2M | 21.8M |
| Cash & Short-term Investments | 7.52M | 3.71M | 9.38M | 5.51M | 12.6M | 34.0M | 17.8M | 39.0M | 34.6M | 54.2M | 19.2M |
| Total Debt | 2.68M | - | - | 1.02M | 1.40M | 1.20M | 1.61M | 1.60M | 2.34M | 3.29M | 1.71M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.50M | -8.13M | -7.61M | -9.81M | -9.08M | -13.2M | -15.5M | -16.4M | -21.9M | -35.1M | -45.1M |
| Capital Expenditure | 49.0K | 258K | 67.0K | 284K | 88.0K | 344K | 473K | 381K | 1.40M | 1.66M | 1.04M |
| Free Cash Flow | -7.54M | -8.39M | -7.67M | -10.1M | -9.17M | -13.6M | -16.0M | -16.8M | -23.3M | -36.8M | -46.2M |
| Ratios | |||||||||||
| ROE | -209.2% | -309.4% | -82.6% | -186.5% | -86.7% | -44.5% | -106.3% | -50.4% | -88.7% | -88.4% | -145.9% |
| ROA | -89.9% | -138.2% | -58.9% | -101.6% | -59.3% | -37.6% | -75.0% | -41.8% | -68.4% | -70.3% | -94.5% |
| Net Profit Margin | -446.7% | -305.6% | -201.1% | -269.8% | -424.3% | -331.9% | -357.6% | -321.0% | -456.6% | -543.3% | -321.1% |
| Debt to Equity | 0.66x | - | - | 0.19x | 0.12x | 0.04x | 0.09x | 0.04x | 0.06x | 0.06x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
InspireMD Inc dividends
InspireMD Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Apr 27, 2021.
Who owns InspireMD Inc
- Insiders 19.85%
- Institutions 46.27%
- Public & others 33.89%
- Shares outstanding 46.8M
- Free float 28.7M
Top funds holding NSPR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn Healthcare Investors | 1.74M | 3.70% | 0.00% | Oct 2026 |
| abrdn Healthcare Opportunities | 1.26M | 2.67% | 0.00% | Sep 2026 |
| abrdn World Healthcare | 695K | 1.48% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 104K | 0.22% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 9.77K | 0.02% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 8.16K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding NSPR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6.75M | 14.33% | +100.00% | Jun 2026 |
| Rosalind Advisors, Inc. | 3.91M | 8.29% | 0.00% | Jun 2026 |
| Aberdeen Group PLC | 3.70M | 7.85% | 0.00% | Sep 2026 |
| Orbimed Advisors LLC | 3.13M | 6.65% | 0.00% | Jun 2026 |
| Parkman Healthcare Partners LLC | 2.42M | 5.13% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.86M | 3.95% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.05M | 2.22% | 0.00% | Jun 2026 |
| PURA VIDA INVESTMENTS, LLC | 451K | 0.96% | 0.00% | Jun 2026 |
| Ingalls & Snyder LLC | 369K | 0.78% | -2.77% | Jun 2026 |
| Affiance Financial LLC | 250K | 0.53% | 0.00% | Sep 2026 |
| Velan Capital Investment Management LP | 148K | 0.31% | -92.94% | Jun 2026 |
| BlackRock Inc | 123K | 0.26% | +52.88% | Jun 2026 |
| Creative Planning Inc | 109K | 0.23% | +452.72% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 99.3K | 0.21% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 87.9K | 0.19% | -22.10% | Sep 2026 |
| HRT FINANCIAL LLC | 59.8K | 0.13% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 49.0K | 0.10% | +296.74% | Jun 2026 |
| Centiva Capital LP | 44.1K | 0.09% | +78.16% | Jun 2026 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 40.3K | 0.09% | 0.00% | Jun 2026 |
| Millennium Management LLC | 37.7K | 0.08% | -66.49% | Jun 2026 |
InspireMD Inc company profile
- Company name
- InspireMD Inc
- Ticker
- NSPR.US
- Exchange
- USA Stocks
- Listed since
- Apr 12, 2011
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 127
- Fiscal year end
- December
- Address
- 6303 Waterford District Drive, Miami, FL, United States, 33126
- Phone
- 888 776 6804
- Website
- inspiremd.com
About InspireMD Inc
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
InspireMD Inc management
9- Mr. Marvin L. SlosmanPresident, CEO & Director · born 1964
- Mr. Michael A. LawlessCFO, Secretary & Treasurer · born 1969
- Mr. Vince TurturroSenior Vice President of Global Operations & Engineering
- Ms. Kathleen KennedySenior Vice President of Global Sales & Marketing
- Ms. Donna DeChantVice President of Human Resources & Organizational Development
- Mr. Amir KohenExecutive VP of Finance & Regional Manager
- Dr. Peter A. Soukas M.D.Chief Medical Officer
- Ms. Sonali DewanSenior Vice President of Regulatory & Medical Affairs and Quality Assurance
- Dr. Sol J. Barer Ph.D.Special Advisor to the Board · born 1947